Investor Presentation
Filed with ASX · · 18 pages · English
Summary by 6ix AI
Invion Ltd. has released an investor presentation detailing its innovative PhotosoftTM technology for treating various cancers and infectious diseases. The presentation outlines the company's participation in upcoming conferences and highlights its clinical development plans. It emphasizes the potential of PhotosoftTM as a next-generation photodynamic therapy, showcasing preclinical results and market opportunities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Invion
- Photosoft Territory Expanded to South Korea for Cancer
- Appendix 4E and Preliminary Financial Report
- Expansion of Territory Rights to USA, Canada and Hong Kong
- INV043 Effective Against Anal Cancer SCC In Vitro
- Response to ASX Aware Query
Later from Invion
- Major Milestone towards Clinical Trials
- AGM Presentation
- Agreement with Dr.inB to develop Photosoft treatment for HPV
- INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC
- Agreement with Major South Korean Pharma Group Hanlim
Follow Invion into a list and get an email when it puts out news.
Follow Invion